ID

16108

Descrizione

A Comparison of Exenatide and Insulin Glargine on Glycemic Variability in Type 2 Diabetes Patients Inadequately Controlled With Metformin Monotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02325960

collegamento

https://clinicaltrials.gov/show/NCT02325960

Keywords

versioni (1)
  1. 29/06/16 29/06/16 -
Caricato su

29 giugno 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Type 2 Diabetes NCT02325960

Inglese

Eligibility Type 2 Diabetes NCT02325960

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. provision of informed consent prior to any study specific procedures
Descrizione

Informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
2. type2 diabetic patients had been on stable, maximum tolerated doses of metformin (≧1500mg/d, ≧8 weeks)
Descrizione

Diabetes Mellitus, Non-Insulin-Dependent | Metformin Maximum Dosage Stable

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0806909
UMLS CUI [2,3]
C0178602
UMLS CUI [2,4]
C0205360
3. male or female age ≧ 18 years and ≦70 years old
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
4. hba1c ≧7.0 and ≦10%
Descrizione

Hemoglobin A1c measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0474680
5. bmi ≧ 24 kg/m2
Descrizione

Body mass index

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. known or suspected allergy to trial products or related products.
Descrizione

Hypersensitivity Investigational New Drugs | Hypersensitivity Investigational New Drugs Related Pharmaceutical Preparations

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0013230
UMLS CUI [2,3]
C0439849
UMLS CUI [2,4]
C0013227
2. impaired renal function defined as serum-creatinine ≥ 1.5 mg/dl (≥ 133 umol/l).
Descrizione

Renal Insufficiency | Creatinine measurement, serum

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
3. acute or chronic disease which may cause tissue hypoxia such as respiratory failure or shock.
Descrizione

Disease Causing Tissue hypoxia | Respiratory Failure | Shock

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0678227
UMLS CUI [1,3]
C4061096
UMLS CUI [2]
C1145670
UMLS CUI [3]
C0036974
4. abnormal liver function, alanine transaminase or aspartate aminotransferase ≥ 3 fold normal upper limit, total bilirubin ≥ 2 normal upper limit, acute alcohol intoxication, alcoholism.
Descrizione

Liver Dysfunction | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Bilirubin, total measurement | Acute alcoholic intoxication | Alcoholic Intoxication, Chronic

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C0201836
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201913
UMLS CUI [5]
C0394996
UMLS CUI [6]
C0001973
5. subjects has a clinically significant, active (or over the past 12 months) cardiovascular history (including a history of myocardial infarction (mi), arrhythmias or conduction delays on ecg, unstable angina, or decompensated heart failure (new york heart association-class ⅲ and ⅳ).
Descrizione

Cardiovascular Diseases Clinical Significance | Myocardial Infarction | Cardiac Arrhythmia | Electrocardiography Conduction delay | Angina, Unstable | Decompensated cardiac failure

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C2826293
UMLS CUI [2]
C0027051
UMLS CUI [3]
C0003811
UMLS CUI [4,1]
C1623258
UMLS CUI [4,2]
C1398354
UMLS CUI [5]
C0002965
UMLS CUI [6]
C0581377
6. proliferative retinopathy or muscular oedema requiring acute treatment.
Descrizione

Proliferative retinopathy Requirement Therapeutic procedure | Muscular edema Requirement Therapeutic procedure

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0339467
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0087111
UMLS CUI [2,1]
C4021979
UMLS CUI [2,2]
C1514873
UMLS CUI [2,3]
C0087111
7. pregnant or positive pregnancy test at screening, nursing mother, or unwillingness to use adequate contraception (adequate contraceptive measures are sterilization, intrauterine device, oral contraceptives or barrier methods).
Descrizione

Pregnancy | Pregnancy test positive | Breast Feeding | Contraceptive methods Unwilling | Female Sterilization | Intrauterine Devices | Contraceptives, Oral | Contraception, Barrier

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0240802
UMLS CUI [3]
C0006147
UMLS CUI [4,1]
C0700589
UMLS CUI [4,2]
C0558080
UMLS CUI [5]
C0015787
UMLS CUI [6]
C0021900
UMLS CUI [7]
C0009905
UMLS CUI [8]
C0004764
8. treatment with systemic corticosteroids within the past two months prior to screening.
Descrizione

Therapeutic procedure systemic steroids

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C2825233
9. type 1 diabetes mellitus.
Descrizione

Diabetes Mellitus, Insulin-Dependent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011854
10. receipt of any investigational drug within 1 month prior to this trial.
Descrizione

Investigational New Drugs Use

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C1524063
Ritorna all'inizio della pagina

Similar models

Eligibility Type 2 Diabetes NCT02325960

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Informed consent
Item
1. provision of informed consent prior to any study specific procedures
boolean
C0021430 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent | Metformin Maximum Dosage Stable
Item
2. type2 diabetic patients had been on stable, maximum tolerated doses of metformin (≧1500mg/d, ≧8 weeks)
boolean
C0011860 (UMLS CUI [1])
C0025598 (UMLS CUI [2,1])
C0806909 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
C0205360 (UMLS CUI [2,4])
Age
Item
3. male or female age ≧ 18 years and ≦70 years old
boolean
C0001779 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
4. hba1c ≧7.0 and ≦10%
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
5. bmi ≧ 24 kg/m2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Investigational New Drugs | Hypersensitivity Investigational New Drugs Related Pharmaceutical Preparations
Item
1. known or suspected allergy to trial products or related products.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0013227 (UMLS CUI [2,4])
Renal Insufficiency | Creatinine measurement, serum
Item
2. impaired renal function defined as serum-creatinine ≥ 1.5 mg/dl (≥ 133 umol/l).
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Disease Causing Tissue hypoxia | Respiratory Failure | Shock
Item
3. acute or chronic disease which may cause tissue hypoxia such as respiratory failure or shock.
boolean
C0012634 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C4061096 (UMLS CUI [1,3])
C1145670 (UMLS CUI [2])
C0036974 (UMLS CUI [3])
Liver Dysfunction | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Bilirubin, total measurement | Acute alcoholic intoxication | Alcoholic Intoxication, Chronic
Item
4. abnormal liver function, alanine transaminase or aspartate aminotransferase ≥ 3 fold normal upper limit, total bilirubin ≥ 2 normal upper limit, acute alcohol intoxication, alcoholism.
boolean
C0086565 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201913 (UMLS CUI [4])
C0394996 (UMLS CUI [5])
C0001973 (UMLS CUI [6])
Cardiovascular Diseases Clinical Significance | Myocardial Infarction | Cardiac Arrhythmia | Electrocardiography Conduction delay | Angina, Unstable | Decompensated cardiac failure
Item
5. subjects has a clinically significant, active (or over the past 12 months) cardiovascular history (including a history of myocardial infarction (mi), arrhythmias or conduction delays on ecg, unstable angina, or decompensated heart failure (new york heart association-class ⅲ and ⅳ).
boolean
C0007222 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0027051 (UMLS CUI [2])
C0003811 (UMLS CUI [3])
C1623258 (UMLS CUI [4,1])
C1398354 (UMLS CUI [4,2])
C0002965 (UMLS CUI [5])
C0581377 (UMLS CUI [6])
Proliferative retinopathy Requirement Therapeutic procedure | Muscular edema Requirement Therapeutic procedure
Item
6. proliferative retinopathy or muscular oedema requiring acute treatment.
boolean
C0339467 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C4021979 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
Pregnancy | Pregnancy test positive | Breast Feeding | Contraceptive methods Unwilling | Female Sterilization | Intrauterine Devices | Contraceptives, Oral | Contraception, Barrier
Item
7. pregnant or positive pregnancy test at screening, nursing mother, or unwillingness to use adequate contraception (adequate contraceptive measures are sterilization, intrauterine device, oral contraceptives or barrier methods).
boolean
C0032961 (UMLS CUI [1])
C0240802 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
C0700589 (UMLS CUI [4,1])
C0558080 (UMLS CUI [4,2])
C0015787 (UMLS CUI [5])
C0021900 (UMLS CUI [6])
C0009905 (UMLS CUI [7])
C0004764 (UMLS CUI [8])
Therapeutic procedure systemic steroids
Item
8. treatment with systemic corticosteroids within the past two months prior to screening.
boolean
C0087111 (UMLS CUI [1,1])
C2825233 (UMLS CUI [1,2])
Diabetes Mellitus, Insulin-Dependent
Item
9. type 1 diabetes mellitus.
boolean
C0011854 (UMLS CUI [1])
Investigational New Drugs Use
Item
10. receipt of any investigational drug within 1 month prior to this trial.
boolean
C0013230 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial